Sveriges mest populära poddar
Pharmaceutical Executive
VetenskapLife Science

Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO

3 min•10 juni 2026
In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech AlzeCure Pharma enters a collaboration and out-licensing agreement with Eli Lilly for its Alzheimer's candidate, and FDA approves an every-eight-week maintenance dosing regimen for Eli Lilly's Ebglyss.

Fler avsnitt av Pharmaceutical Executive

Visa alla avsnitt av Pharmaceutical Executive
Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization
•3 min
Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge
•3 min
Pharmaceutical Executive Daily: FDA Names Seven Participants to Precheck Program
•3 min
Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics
•4 min
Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
•3 min
Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration
•3 min
Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts
•4 min
Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion
•3 min
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
•4 min
Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive
•4 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.